Bisphosphonates (BPs) and denosumab reduce the risk of spine and nonspine fractures.
Atypical femur fractures (AFFs) located in the subtrochanteric region and diaphysis of the femur …

Measures of musculoskeletal rehabilitation play an integral part in the management of
patients with increased fracture risk because of osteoporosis or extraskeletal risk factors. This …

The European League Against Rheumatism (EULAR) and the European Federation of
National Associations of Orthopaedics and Traumatology (EFORT) have recognised the …

Background Risedronate increases bone mineral density in elderly women, but whether it
prevents hip fracture is not known. Methods We studied 5445 women 70 to 79 years old who …

ContextVertebral fractures significantly increase lifetime risk of future fractures, but risk of
further vertebral fractures in the period immediately following a vertebral fracture has not been …

Reports linking long‐term use of bisphosphonates (BPs) with atypical fractures of the femur
led the leadership of the American Society for Bone and Mineral Research (ASBMR) to …

… van der Heijde, Dijkmans, Geusens, Sieper, and Braun have received research support
from Centocor, Inc. and have received consulting fees or honoraria totaling less than $10,000 …

Objective To determine whether patients with rheumatoid arthritis (RA) have an increased
risk of fracture, and to estimate their long‐term absolute fracture risk. Methods We studied …

In the present study, we examined the expression of regulators of bone formation and
osteoclastogenesis in human atherosclerosis because accumulating evidence suggests that …

Background No clinical trials have compared osteoporosis drugs with incident fractures as
the primary outcome. We compared the anti-fracture efficacy of teriparatide with risedronate in …